Skip to main content

$0.315 0.010 (3.28%)

High

$0.32

Low

$0.30

Trades

243

Turnover

$627,825

Volume

2,012,212
30 June 2023 at 4:10pm
Register to track IMM and receive email alerts.
Subject
IMM Article: Immutep raises $100m and signs with Merck on ‘blockbuster’ drug

IMM Article: Biotech Immutep seeks $102 million, taps three brokers

IMM Article: Perennial fundie’s top small-cap healthcare picks

IMM Ann: Application for quotation of securities - IMM

IMM Ann: US patent granted for Efti with PD-1 pathway inhibitor

IMM Ann: Immutep completes underwritten retail entitlement offer

IMM Ann: Immutep granted US patent for IMP761 agonist LAG-3 antibody

IMM Ann: Change in substantial holding from IFL

IMM Ann: Change in substantial holding

IMM Ann: Change in substantial holding

IMM Ann: Becoming a substantial holder

IMM Ann: Cleansing Notice

IMM Ann: Application for quotation of securities - IMM

IMM Ann: Immutep letter to ineligible shareholders

IMM Ann: Immutep retail entitlement offer booklet

IMM Ann: Positive final data in 2nd line head and neck cancer at ASCO

IMM Article: Fundies pile into Immutep $80m raise

IMM Ann: Immutep completes institutional pro-rata offer & placement

IMM Ann: Change in substantial holding

IMM Article: Immutep in $80m raise; Bells, Jefferies and Wilsons on ticket

IMM Ann: Cleansing Notice

IMM Ann: Proposed issue of securities - IMM

IMM Ann: Immutep Capital Raising Presentation

IMM Ann: A$80 million fully underwritten equity raising

IMM Ann: Trading Halt

IMM Ann: Charles River Laboratories to run IMP761 Toxicology Study

IMM Ann: Publication of Abstracts for ASCO 2023 Annual Meeting

IMM Ann: 1st patient dosed in AIPAC-003 ph2/3 breast cancer trial

IMM Ann: Promising New Data in 1st line NSCLC from INSIGHT-003 Trial

IMM Ann: Excellent initial Overall Survival Benefit in 1st line NSCLC

IMM Ann: FDA supportive of Efti registrational trial in lung cancer

IMM Ann: Change of Director's Interest Notice - R Howard

IMM Ann: Approval to start Efti & Bavencio trial in urothelial cancer

IMM Ann: Immutep Quarterly Activities Report and Appendix 4C

IMM Ann: Immutep to announce new TACTI-002 data at ASCO 2023

IMM Ann: Immutep appoints Dr Florian Vogl as Chief Medical Officer

IMM Ann: Response to ASX Aware Query

IMM Ann: Initiation of Phase 2 Trial for Efti in Soft Tissue Sarcoma

IMM Ann: Notification of cessation of securities - IMM

IMM Article: ASX to edge higher; Newmont increases bid for Newcrest

IMM Ann: Appendix 3Z - Lucy Turnbull

IMM Ann: Appendix 3X - Lis Boyce

IMM Ann: Immutep Announces Changes to the Board

IMM Ann: Positive Final Data in 2nd Line Metastatic NSCLC Patients

IMM Ann: Change in substantial holding

IMM Ann: Expansion of INSIGHT-003 trial for Efti in 1st Line NSCLC

IMM Ann: Abstract accepted for ESMO's European Lung Cancer Congress

IMM Ann: Initiation of Ph 2/3 Trial for Metastatic Breast Cancer

IMM Ann: Half Yearly Report and Accounts

IMM Ann: Enrolment Target Reached for INSIGHT-003 Trial in NSCLC

Register to track IMM and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMU
MSB
OPT
PAR
PYC
RAC
TLX